Clinical Trial Update: Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of Genasense (oblimersen sodium) in chronic lymphocytic leukemia sponsored by Genta Incorporated has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Genasense (oblimersen)

Snippet

Sponsor: Genta Incorporated | Conditions: Chronic Lymphocytic Leukemia, CLL | Phase 1, Phase 2 | Status: COMPLETED